Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Single Arm Study of Intravesical Administration With Camrelizumab for High-risk Non-muscle Invasive Bladder Cancer(NMIBC) Failing in BCG Treatment

NCT04706598 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04706598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04706598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Single Arm Study of Intravesical Administration With Camrelizumab for High-risk Non-muscle Invasive Bladder Cancer(NMIBC) Failing in BCG Treatment
Lead sponsor
Fudan University
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 9, 2021
Completion date
December 31, 2026
Enrollment
25 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy, urinary bladder neoplasms